Cocrystal Pharma Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with CC-42344, a Novel, Broad-Spectrum Influenza A antiviral
April 12, 2022 08:00 ET
|
Cocrystal Pharma, Inc.
CC-42344 administered orally as a single 100 mg or 200 mg dose in healthy adults showed a favorable safety and pharmacokinetic profile BOTHELL, Wash., April 12, 2022 (GLOBE NEWSWIRE) -- Cocrystal...
Cocrystal Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company, announces that management will...
Cocrystal Pharma Reports Second Quarter 2021 Financial Results and Provides Antiviral Program and Milestone Updates
August 16, 2021 08:00 ET
|
Cocrystal Pharma, Inc.
Influenza program Phase 1 clinical trial with CC-42344 on track to begin in the third quarter of 2021COVID-19 program preclinical development with the novel oral SARS-CoV-2 protease inhibitors is...
Cocrystal Pharma Reports Third Quarter 2020 Financial Results and Provides Update on Antiviral Programs
November 16, 2020 08:05 ET
|
Cocrystal Pharma, Inc.
– Continued progress of COVID-19 development programs with additional preclinical studies of coronavirus protease inhibitors (3CL) underway and lead preclinical molecule selection expected by year end...
Cocrystal Pharma Reports 2019 Financial Results and Outlines Expected Value-Driving Milestones for 2020
March 30, 2020 06:05 ET
|
Cocrystal Pharma, Inc.
Advancing preclinical COVID-19 Coronavirus program leveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”) Continuing collaboration with Merck to discover...
Cocrystal Pharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update
August 09, 2019 08:05 ET
|
Cocrystal Pharma, Inc.
– Company continues to drive clinical and research programs forward to achieve multiple value-driving milestones– – Business development initiative underway with active discussions ongoing to secure...
Cocrystal Pharma Commences Patient Enrollment for Hong Kong Phase 2a Study of CC-31244 for Ultra-Short Treatment of Hepatitis C Virus
May 20, 2019 08:05 ET
|
Cocrystal Pharma, Inc.
- Humanity & Health Research Centre conducting differentiated Phase 2a study evaluating CC-31244 for the ultra-short treatment of hepatitis C (HepC) - Asia market represents one of the largest...
Cocrystal Pharma Announces Presentation at the RespiDART 2018: Frontiers in Drug Development Against Respiratory Viruses Conference
November 30, 2018 08:00 ET
|
Cocrystal Pharma, Inc.
- Proprietary technology has the ability to fuel Cocrystal’s pipeline by effectively creating small molecule antiviral therapeutics that are safe, effective, convenient to administer and have the...
Cocrystal Pharma Announces Presentation of Preclinical Characterization Data of CC-42344 at the 6th ISIRV-AVG Conference
November 13, 2018 11:50 ET
|
Cocrystal Pharma, Inc.
- Company’s novel, broad spectrum influenza antivirals specifically designed to be effective against all significant A strains of the influenza virus - - CC-43244, Company’s lead molecule has...
Cocrystal Pharma to Present at the Fred Hutch and Merck Infectious Disease Summit
May 10, 2018 08:30 ET
|
Cocrystal Pharma, Inc.
- Presentation on Thursday, May 10 at 11:15 AM PDT - ATLANTA, GA and BOTHELL, WA, May 10, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical...